Do we need patient-specific QA for adaptively generated plans? Retrospective evaluation of delivered online adaptive treatment plans on Varian Ethos.

Abstract

The clinical introduction of dedicated treatment units for online adaptive radiation therapy (OART) has led to widespread adoption of daily adaptive radiotherapy. OART allows for rapid generation of treatment plans using daily patient anatomy, potentially leading to reduction of treatment margins and increased normal tissue sparing. However, the OART workflow does not allow for measurement of patient-specific quality assurance (PSQA) during treatment delivery sessions and instead relies on secondary dose calculations for verification of adapted plans. It remains unknown if independent dose verification is a sufficient surrogate for PSQA measurements. To evaluate the plan quality of previously treated adaptive plans through multiple standard PSQA measurements. This IRB-approved retrospective study included sixteen patients previously treated with OART at our institution. PSQA measurements were performed for each patient's scheduled and adaptive plans: five adaptive plans were randomly selected to perform ion chamber measurements and two adaptive plans were randomly selected for ArcCHECK measurements. The same ArcCHECK 3D dose distribution was also sent to Mobius3D to evaluate the second-check dosimetry system. All (n=96) ion chamber measurements agreed with the planned dose within 3% with a mean of 1.4% (±0.7%). All (n=48) plans passed ArcCHECK measurements using a 95% gamma passing threshold and 3%/2mm criteria with a mean of 99.1% (±0.7%). All (n=48) plans passed Mobius3D second-check performed with 95% gamma passing threshold and 5%/3mm criteria with a mean of 99.0% (±0.2%). Plan measurement for PSQA may not be necessary for every online-adaptive treatment verification. We recommend the establishment of a periodic PSQA check to better understand trends in passing rates for delivered adaptive treatments.